Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2008-10-06 Investor Presentation
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
POH Presentation - Annual Pain Therapeutics Summit 2008 32 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Phosphagenics Limited at the Annual Pain Therapeutics Summit 2008, as indicated by the heading and content. It includes extensive information about the company's technology, management, pre-clinical and clinical data, and market positioning. The document is a presentation given at a conference, not a financial report, regulatory filing, or announcement of voting results. It is not an earnings release or an annual/interim report. The content matches the description of an Investor Presentation, which focuses on financials, strategy, and market position, often used to inform investors and stakeholders about the company's business and technology developments. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2008-10-06 English
Change of Director`s Interest Notice Professor J Mills 4 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Change of Director’s Interest Notice – Professor J Mills' and references an Appendix 3Y Notice, which is a standard form used in Australian Securities Exchange (ASX) filings to disclose changes in directors' shareholdings. The content details the purchase of shares by a director, including dates, number of shares, and prices. There is no financial performance data, earnings information, or management discussion. The document is a regulatory disclosure about insider trading activity by a director, consistent with the definition of Director's Dealing filings. Therefore, the document fits the category of Director's Dealing (DIRS). The document length is sufficient and contains detailed information about the director's share transactions, confirming the classification with high confidence.
2008-10-02 English
Initiation of Phase 1 Clinical Trial Transdermal Lidocaine 2 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a company announcement dated 23rd September 2008 from Phosphagenics Limited. It announces the initiation of a Phase 1 clinical trial for a transdermal lidocaine product. The content focuses on the clinical trial start, pre-clinical results, and expectations for reporting trial results in the future. There are no financial statements, regulatory filings, or detailed financial data presented. The document is a press release announcing a clinical trial initiation, which is a typical corporate announcement rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement either, as it does not mention the release of a report but rather announces a new clinical trial. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2008-09-22 English
AIM Update 2 pages ?Kb
Delisting Announcement Classification · 95% confidence The document is a company announcement dated 22 September 2008 regarding the cancellation of the company's securities admission to trading on the AIM market. It discusses the decision by the Board to delist from AIM, the transfer of registers, and trading arrangements on the ASX. There are no financial statements, detailed financial data, or management discussion of results. The document is an official notice about the delisting of the company's shares from AIM. Therefore, it fits the definition of a Delisting Announcement (DLST). The document length is under 5,000 characters and is a direct announcement, not a report publication or regulatory filing. Hence, the classification is DLST with high confidence.
2008-09-21 English
Revised Form 603 - NextGen Pet Ltd 25 pages ?Kb
Regulatory Filings
2008-09-17 English
Becoming a substantial holder 25 pages ?Kb
Regulatory Filings
2008-09-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.